Akero Therapeutics, Inc.
Akero Therapeutics, Inc.（AKRO）内幕交易
基于 SEC Form 4 的买入/卖出笔数、买卖比与情绪标签；可在本季度与近12个月之间切换；下方为季度图与交易明细。
SEC EDGAR · FMP · AKRO · 截至 2026年6月8日
活动摘要
买入笔数
4
P-Purchase only
卖出笔数
118
近12个月
买卖比
0.03
Buy/Sell (by trades)
整体情绪
Akero Therapeutics, Inc.内部人在过去近12个月主要在卖出股份，卖出行为通常由预设的Rule 10b5-1计划驱动，不一定代表对公司的负面看法。
▸ 数据来源：SEC EDGAR · Form 3 & 4 · 买入仅计P-Purchase · 卖出仅计S-Sale
截至 2026年6月8日
AKRO 季度内部人买卖趋势
AKRO 内幕交易卖出 · AKRO 内幕交易买入 · 季度活动
Mobile shows last 4Q · Desktop shows full 8Q
▸ 数据来源：SEC EDGAR · Form 3 & 4 · 最近8季度
As of Jun 8, 2026
活跃内部人
近12个月交易最活跃 · AKRO CEO内幕交易
显示全部内部人 · 点击卡片过滤下方交易表
▸ 按reportingName聚合 · 近12月交易次数Top5 · 无额外API
近期内幕交易记录
AKRO 高管卖出股份 · AKRO 董事内幕交易 · SEC Form 4申报
横向滑动查看全部列
| 日期 | 内部人 | 类型 | 股数 | 总金额 | 申报 |
|---|---|---|---|---|---|
| Dec 9, 2025 | Heyman Tomas J. Director | Other | 9,398 | — | Form 4 |
| Dec 9, 2025 | Xu Yuan Director | Other | 9,398 | — | Form 4 |
| Dec 9, 2025 | Cheng Andrew President and CEO · Director | Other | 159,762 | — | Form 4 |
| Dec 9, 2025 | Harrison Seth Loring Director | Other | 9,398 | — | Form 4 |
| Dec 9, 2025 | Graham G. Walmsley Director | Other | 9,398 | — | Form 4 |
| Dec 9, 2025 | Judy Chou Director | Other | 9,398 | — | Form 4 |
| Dec 9, 2025 | Rolph Timothy Chief Scientific Officer | Other | 43,810 | — | Form 4 |
| Dec 9, 2025 | Iwicki Mark T Director | Other | 9,398 | — | Form 4 |
| Dec 9, 2025 | Gangloff Scott A. CTO | Other | 21,263 | — | Form 4 |
| Dec 9, 2025 | White William Richard CFO | Other | 47,573 | — | Form 4 |
| Dec 9, 2025 | Yale Catriona Chief Development Officer | Other | 47,573 | — | Form 4 |
| Dec 9, 2025 | Lamy Patrick See Remarks | Other | 26,832 | — | Form 4 |
| Dec 9, 2025 | Henderson Jane Director | Other | 9,398 | — | Form 4 |
| Dec 9, 2025 | Young Jonathan COO | Other | 47,573 | — | Form 4 |
| Nov 25, 2025 | Rolph Timothy Chief Scientific Officer | Option | 4,739 | $100K | Form 4 |
| Nov 25, 2025 | Rolph Timothy Chief Scientific Officer | Option | 94,268 | $58K | Form 4 |
| Nov 25, 2025 | Rolph Timothy Chief Scientific Officer | Option | 2,796 | $2K | Form 4 |
| Nov 25, 2025 | Rolph Timothy Chief Scientific Officer | Option | 4,284 | $90K | Form 4 |
| Nov 25, 2025 | Rolph Timothy Chief Scientific Officer | Option | 43,064 | $274K | Form 4 |
| Nov 25, 2025 | Rolph Timothy Chief Scientific Officer | Option | 3,527 | $100K | Form 4 |
| Nov 24, 2025 | Young Jonathan COO | Option | 4,739 | $100K | Form 4 |
| Nov 24, 2025 | Young Jonathan COO | Option | 3,527 | $100K | Form 4 |
| Nov 24, 2025 | Young Jonathan COO | Option | 4,284 | $90K | Form 4 |
| Nov 26, 2025 | Young Jonathan COO | Gift | 9,259 | — | Form 4 |
▸ 数据来源：SEC EDGAR · Form 4 申报 · ⚡ = 金额≥$100万 · Award/Option 价格显示 —
关于 AKRO 内幕交易
AKRO 内幕交易
Akero Therapeutics, Inc.（AKRO）内幕交易数据来源于公司内部人（包括Rolph Timothy (Chief Scientific Officer), Young Jonathan (COO), Heyman Tomas J. (Director)）提交的SEC Form 4申报文件。过去12个月内，5位内部人向SEC提交了交易申报。AKRO内部人近期主要在卖出，这可能反映预设的10b5-1计划执行，而非方向性判断。
如需查看Akero Therapeutics, Inc.机构持仓比例和内部人持股百分比，请访问持仓（Ownership）标签页 → Ownership tab →
常见问题
AKRO 内幕交易 · 5个问题Akero Therapeutics, Inc.（AKRO）的内部人包括高管和董事，如Rolph Timothy (Chief Scientific Officer), Young Jonathan (COO), Heyman Tomas J. (Director)等。过去12个月内，5位内部人向SEC提交了Form 4交易申报。内部人须在交易日期后2个工作日内完成申报。
▸ 数据来源：FMP /stable/insider-trading/search · SEC EDGAR Form 3 & 4 · RSU归属不计入情绪 · As of Jun 8, 2026